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lung defense, but the relationship between
CFTR function and protection from progressive
airway infection and inflammation is uncertain.
Although CFTR functions as a cAMP-regulated
chloride channel (1,2), this property may not
account for the spectrum of abnormalities ob-
served in CF airway epithelia. A second func-
tion for CFTR, as a regulator of other ion chan-
nels, has more recently been described. For
example, the loss of inhibitory effects on the
epithelial sodium channel due to absent or mu-
tated CFTR leads to sodium hyperabsorption
Abstract
Background: Cystic fibrosis (CF) is a syndrome caused
by mutations in the cystic fibrosis transmembrane
regulator (CFTR) gene. Despite advances in our un-
derstanding of the molecular pathogenesis of CF, the
link between CFTR gene mutations and the patho-
genesis of CF lung disease remains poorly defined.
CFTR has been assigned a number of putative func-
tions that may contribute to innate airway defense,
including the regulation of adenosine 5-triphosphate
(ATP) release into the extracellular environment. Because
extracellular ATP and uridine 5-triphosphate (UTP)
may regulate airway mucociliary clearance via inter-
action with luminal P2Y2 receptors, the loss of
CFTR-mediated nucleotide release could explain the
defect in CF airway defense. 
Materials and Methods: We tested the physiologic
importance of CFTR-mediated nucleotide release in
vivo by directly measuring levels of ATP and UTP in
nasal airway surface liquid from normal and CF sub-
jects. Because these basal nucleotide levels reflect
the net activities of nucleotide release and metabolic
pathways, we also measured constitutive rates of nu-
cleotide release and metabolism on well-differentiated
normal and CF airway cultures in vitro. The mea-
surement of ATP release rates were paralleled by in
vivo studies employing continuous nasal perfusion
in normal and CF subjects. Finally, the regulation of
ATP release by isoproterenol and methacholine-
stimulated submucosal gland secretion was tested.
Results: These studies revealed that steady-state
ATP and UTP levels were similar in normal (470 
131 nM and 37  7 nM, respectively) and CF (911 
199 nM and 33  12 nM, respectively) subjects. The
rates of both ATP release and metabolism were also
similar in normal and CF airway epithelia both in
vitro and in vivo. Airway submucosal glands did not
secrete nucleotides, but rather, secreted a soluble
nucleotidase in response to cholinergic stimuli.
Conclusion: The concentration of ATP in airway
surface liquid is in a range that is relevant for the ac-
tivation of airway nucleotide receptors. However, 
despite this finding that suggests endogenous nucleo-
tides may be important for the regulation of mu-
cociliary clearance, our data do not support a role for
CFTR in regulating extracellular nucleotide concen-
trations on airway surfaces.
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Introduction
Cystic fibrosis (CF) is a monogenetic disease
characterized by chronic airway infection and
bronchiectasis that is caused by mutations in the
cystic fibrosis transmembrane regulator (CFTR)
gene. It is clear that CF patients have impaired
970 Molecular Medicine, Volume 6, Number 11, November 2000
(3,4), which may contribute to CF airway dis-
ease pathogenesis (5,6). A third function pro-
posed for CFTR is as an ATP channel and/or
regulator of ATP release (7–14). Since ATP can
regulate mucociliary clearance via airway P2Y2
nucleotide receptors (15,16) by increasing cilia
beat frequency (17–19), chloride secretion
(20,21), and goblet cell degranulation (22,23),
mutations in CFTR could lead to a reduced ATP
concentration on airway surfaces and adversely
affect lung defense.
The earliest notion that CFTR may be in-
volved in ATP transport emanated from studies
of the multi-drug resistance protein (MDR),
which like CFTR, is a member of the ATP-
binding cassette (ABC) family of transporters
(24). Subsequently, a number of in vitro studies
showed either direct ATP conduction through
CFTR using patch clamp techniques, or evi-
dence for a direct relationship between normal
CFTR expression and ATP release (7–14). Con-
flicting with these reports, however, are studies
using a variety of methodologies that could not
detect CFTR-dependent ATP release (25–29). It
may be difficult to resolve these discrepant re-
sults, because of the wide variety of heterolo-
gous cells and techniques employed. As an
alternative approach, we utilized an in vivo
approach to investigate the relevance of CFTR-
mediated nucleotide release from airway ep-
ithelial cells. 
Using the nose as an in vivo model of hu-
man airways, we measured basal concentra-
tions of ATP and UTP in nasal airway surface
liquid (ASL) from both normal and CF sub-
jects. Because basal nucleotide levels may re-
flect the net activities of steady state cellular 
release and extracellular degradation, we char-
acterized each of these processes. Membrane-
associated nucleotide 5-triphosphate (NTP)
metabolism was measured in normal and CF
nasal epithelial cells. Basal rates of ATP release
were measured in well-differentiated normal
and CF tracheobronchial cell cultures and in
vivo during continuous nasal perfusion. The
possibility of cAMP-dependent regulation of ATP
release by isoproterenol was also tested in vivo.
Materials and Methods
Subjects
Normal (age 30.7  2.2 years; range 21–44
years; n  11) and CF (age 22.5  1.1 years;
range 18–29 years; n  11) subjects without
visible nasal inflammation or recent nasal
symptoms were studied after obtaining in-
formed consent in accordance with the Univer-
sity of North Carolina Human Rights Com-
mittee. For the measurement of basal ATP
concentration in nasal ASL, 11 normal and 11
CF subjects were studied. Basal UTP concen-
tration was measured in five normal and five
CF subjects. In vivo ATP release in response to
isoproterenol and during continuous saline
perfusion was studied in five normal and five
CF subjects. Nasal submucosal gland secre-
tions were obtained from four normal subjects
and three subjects with CF. Normal and CF
nasal and tracheobronchial cells for in vitro
ATP release and metabolism experiments were
harvested from surgical specimens, as described
below. 
Materials
[14C]glucose 1-phosphate and all nucleotides
were obtained from Amersham Pharmacia
(Piscataway, NJ). Tritium labeled ADP and
UDP were prepared from their [3H]NTP precur-
sor by incubating the appropriate substrate
with hexokinase (Roche Molecular Biochemi-
cals; Indianapolis, IN) and glucose (25 mM) for
1 hr at 37C, followed by heat inactivation of
hexokinase by boiling for 2 min. Complete
conversion to the appropriate [3H]NDP was
confirmed using high performance liquid chro-
matography (HPLC). For nasal studies, metha-
choline was purchased from Amend Drug and
Chemical (Irvington, NJ), and ipratropium
bromide from Boehringer Ingelheim (Ridge-
field, CT). All other reagents were purchased
from Sigma (St. Louis, MO). 
Measurement of Basal ATP and UTP Concentrations
in Airway Surface Liquid in vivo
SAMPLE COLLECTION. A sampling device, con-
sisting of a convex shield with a short sam-
pling tube, was used to form a seal with the ex-
ternal nares without contacting the nasal
mucosa. With this device, a 5 ml volume of
saline (37C) was gently instilled into the nasal
cavity over several seconds and immediately
recovered by gravity flow into a sterile con-
tainer. A 1 ml aliquot was immediately assayed
for ATP concentration using the luciferin-
luciferase assay, and the remainder was frozen
for subsequent measurements of UTP and urea
concentrations.
MEASUREMENT OF ATP CONCENTRATION VIA THE LU-
CIFERIN- LUCIFERASE ASSAY. Luminometry (Auto-
Lumat 953; Berthold Analytical Instruments
Inc., Nashua, NH) was performed on a 1 ml
aliquot of nasal lavage by injecting 100 l of
freshly prepared luciferin-luciferase solution
N-2-hydroxyethyl piperazine-N-2-ethanesul-
fonic acid (HEPES) 25 mM; MgCl2 6.25 mM;
EDTA 0.63 mM; dithiothreitol 75 M; bovine
serum albumin (BSA) 1 mg/ml; luciferase 5
g/ml; luciferin 300 M; pH 7.8) into the sam-
ple and measuring light production for 10 sec.
An ATP standard curve was prepared in 1 ml of
0.9% NaCl for each group of sample measure-
ments, and was linear over more than four 
orders of ATP concentration, from 1  1010 to 
5  106 M.
UTP CONCENTRATION ASSAY USING THE UDP-
GLUCOSE PYROPHOSPHORYLASE METHOD. Sam-
ples were boiled, then incubated for 60 min in
0.5 ml Dulbecco’s modified Eagle’s medium
(DMEM)/ HEPES pH 8.0 containing 0.5U/ml
UDP-glucose pyrophosphorylase, 0.5 U/ml inor-
ganic pyrophosphatase, and 1 M [14C]glucose
1-phosphate (0.15 Ci). This coupled enzy-
matic reaction provided quantitative, linear
conversion of UTP to [14C]UDP-glucose in the
1–300 nmol range (30,31). Boiling the samples
for 1 min terminated reactions. The percent
conversion of [14C]glucose 1-phosphate to
[14C]UDP-glucose was determined by HPLC
and compared to a UTP standard curve.
HPLC ANALYSIS. Nucleotides were separated by
HPLC via a Hypersil SAX column (Bodman,
Aston, PA) using a two-solvent system consist-
ing of buffers A (5 mM NH4H2PO4, pH2.8) and
B (375 mM NH4H2PO4, pH 3.7). A linear gra-
dient was developed from 100% buffer A to
80% buffer B over the first 13 min, followed by
an additional 7 min of 100% buffer A. Ab-
sorbance at 264 nm was monitored with an
SPD10A UV detector (Shimadzu, Columbia,
MD), and radioactivity was measured online
with a Flo-One detector (Packard; Meridan, CT).
UREA ASSAY. Measurement of urea concentra-
tion in nasal lavage samples was performed us-
ing the Sigma BUN (Endpoint) diagnostic kit,
as described by the manufacturer. Because
plasma urea measurements were not available
for normal subjects, a normal value of 12 mg/dl
was used for comparison in all cases. All CF
subjects had recent clinical measurements of
blood urea nitrogen (BUN), and none were
outside of the normal range (8–16 mg/dl).
The [urea]/12 quotient was used to normal-
ize each basal ATP and UTP measurement for
the extent of dilution (32).
LACTATE DEHYDROGENASE ASSAY. Nasal lavage
samples obtained for measurement of basal
ATP or UTP concentrations, as well as samples
obtained during nasal perfusion, were assayed
for lactate dehydrogenase activity using a col-
orimetric assay kit as directed by the manufac-
turer (Sigma).
ATP Release from Cultured Airway Epithelial Cells
CELL CULTURE. Well-differentiated human tra-
cheobronchial and nasal epithelial cultures were
produced from normal and CF specimens as pre-
viously described (33). Briefly, cells were har-
vested from surgical specimens (tracheo-
bronchial or nasal turbinate) via protease
digestion and grown on 100 mm tissue culture
dishes in modified bronchiol epithelial growth
media (BEGM) media (Biofluids Inc., Rockville,
MD). With the first passage, cells were seeded on
Costar 12 mm Transwell-Col supports at a den-
sity of 0.25  106/cm2. Upon confluence, the api-
cal surface was rinsed with phosphate-buffered
saline (PBS) thrice weekly, and medium re-
placed only in the basolateral compartment. Cul-
tures were used when they were fully differenti-
ated, approximately 4 weeks after confluence.
ATP RELEASE ASSAY. To quantitate basal ATP 
release, CF and normal tracheobronchial ep-
ithelial cells were gently washed three times
with PBS, then left undisturbed in an incuba-
tor (37C; 5% CO2) for at least 3 hr after adding
500 l minimal essential media (MEM) media
to the apical surface. This incubation period
was determined to be necessary to allow the
ATP concentration in the apical bath to reach
equilibrium. A trace amount of high specific
activity [32P]ATP (0.3 Ci: 3000 Ci/mmole)
then was added to the apical media, which was
calculated to increase the ATP concentration in
the media by 0.15 nM. Samples were ana-
lyzed at various time-points with the luciferin-
luciferase assay to determine ATP concentra-
tion, and HPLC to quantitate the rate of
[32P]ATP metabolism. Under equilibrium
conditions (constant ATP concentration), the
rate of ATP metabolism, as determined by the
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product of the initial rate of [32P]ATP hydrolysis
and the steady-state ATP concentration, was as-
sumed to equal the rate of ATP release. Cells
originating from three normal and two CF pa-
tients were used in these experiments. Mea-
surements from at least three cultures were
made from each patient.
ATP Release in vivo
To test whether there was a basal rate of ATP
release in vivo, a thin polyethylene catheter
was placed under the inferior nasal turbinate
using direct vision and carefully anchored to
maintain stationary positioning. Perfusion
with warmed (37C), isotonic saline was then
initiated at 5 ml/min, and the perfusate al-
lowed to drip from the nose by gravity into a
sterile container. Samples were collected at 1
minute intervals and immediately assayed for
ATP concentration with the luciferin-luciferase
assay. Addition of 15 nM ATP to the super-
fusate resulted in quantitative recovery of the
added ATP in the collected lavage fluid, sug-
gesting little impact on ATP concentration by
surface nucleotidases at this perfusion rate
(data not shown).
To test whether increases in cellular cAMP
induced ATP release in vivo, subjects were
treated with ipratropium bromide (168 g per
nostril) 30–60 min prior to study to inhibit
nasal submucosal gland secretion. 200 l of
warmed (37C) isoproterenol (10 M) or vehi-
cle (0.9% NaCl) was applied to one nostril
with a hand-held nebulizer, followed 2 min
later by lavage with 5 ml of warmed saline us-
ing the sampling technique described with
basal ATP concentration measurements. The
opposite nostril was treated in an identical
fashion with the complementary agent (vehicle
or isoproterenol). Samples obtained by this
method were immediately frozen for subse-
quent analysis of ATP and urea concentrations.
Regulation of ATP Concentration in ASL by Nasal
Submucosal Gland Secretions in vivo
COLLECTION OF NASAL SUBMUCOSAL GLAND SECRE-
TIONS. To study the impact of submucosal gland
(SMG) secretions on luminal ATP concentration,
a baseline nasal lavage was first performed by
delivering a total of 2 ml of 0.9% saline to one
nasal cavity with a hand-held nebulizer (100 l/
actuation). The lavage was recovered by ex-
pelling the liquid from the nose into a sterile
specimen cup after every five actuations. Next,
to obtain a lavage enriched with SMG secre-
tions, methacholine (30 mg, 100 mg/ml solu-
tion) was delivered via nebulizer into the same
nostril, followed 2 min later by a lavage as de-
scribed above. To test the specificity of metha-
choline-induced effects, the opposite nostril was
pretreated with ipratropium bromide (168 g,
42 g/actuation). 15 min later, methacholine
(30 mg) was applied, followed in 2 min by a
nasal lavage as described above. The volume of
each lavage return was measured, mixed 1:1
with a Tris buffer solution [in mM: Tris HCl,
100; MgCl2 , 2; DL-Dithiothreitol (DTT), 3; 
pH 7.4], and incubated (37C for 30 min) with
intermittent vortexing to aid dissolution of the
mucinous secretions. The resulting solutions
were centrifuged (5 min, 600  g) to remove
cells and particulate matter. 
QUANTITATION OF TOTAL ADENINE NUCLEOTIDES IN
NASAL LAVAGES. The initial ATP concentration
in nasal lavages with and without methacholine
treatment was measured using the luciferin-
luciferase assay, as described above. The total
concentration of adenine nucleotides in lavages
was then determined via enzymatic rephos-
phorylation of AMP and ADP to ATP, followed
by the luciferin-luciferase assay, as previously
described (34). Briefly, samples were boiled,
mixed 1:1 with a reaction mixture containing
pyruvate kinase (22 U/ml), adenylate kinase
(100 U/ml), and phosphoenolpyruvate (2.8 mM)
in rephosphorylation buffer (in mM: Hepes,
25; KOH, 15; MgSO4, 10) and incubated at
room temperature for 3 hr. The resulting ATP
concentration was determined with the luciferin-
luciferase assay, using ATP standard curves
prepared in an identical reaction mixture. 
ATP METABOLISM IN NASAL LAVAGES. Reactions
were started by adding [3H]ATP or [33P]ATP
(0.5 Ci/sample; 1–500 M final concentration)
to 0.1 ml of lavage/buffer solution at 37 C and
stopped with 0.5 ml of cold 5% trichloroacetic
acid (TCA). TCA was extracted from the samples
using 8 volumes of ethyl ether. The metabolism
of radiolabeled nucleotides was monitored us-
ing HPLC, as described above. The apparent
Vmax of ATP hydrolysis was determined using
saturating substrate concentrations (0.5 mM),
with reaction times chosen to ensure that 15%
metabolism of the added substrate had occurred.
Comparisons were made between baseline
lavages (no methacholine), lavages enriched
with SMG secretions (post-methacholine), and
lavages performed after ipratropium bromide 	
methacholine. The effect of selected ATPase in-
hibitors were tested, including NaN3 (20 mM),
HgCl2 (10–100 M), ouabain (1 mM), tetramisole
(5 mM), and sodium orthovanadate (1mM). The
requirement for divalent cations was tested with
EGTA (5.0 mM) and EDTA (5.0 mM). Inhibitors
were added to lavage solutions 15 min prior to
the addition of substrate.
Metabolism of Nucleotide Triphosphates by Cultured
Airway Epithelial Cells
Nasal epithelial cell cultures were produced
and maintained as described above. Cultures
were rinsed three times with Krebs buffer
(KBR, in mM: Na+, 140; Cl, 120; K	, 5.2;
HCO3
, 25; HPO4
, 2.4; Ca2	, 1.3; Mg2	, 1.3;
glucose, 5.2; HEPES 25, pH 7.4), then pre-
incubated in bilateral KBR for 30 min (37C,
5% CO2; 350 l apical volume). Reactions were
initiated with the addition of [3H]NTP (1 mM,
final concentration). At designated time points,
a 30 l aliquot was sampled, added to 0.3 ml
ice-cold water, boiled, filtered, and analyzed by
HPLC as described above. Time-points were
chosen so that 15% of the starting material
had been metabolized.
Statistics
Unless otherwise stated, data are reported as
mean  standard error (SE). Multiple samples
obtained from the same subject were averaged
so that the final results are expressed on a per
subject basis. Comparisons were made with
the Student’s t-test, with p  0.05 considered
significant. 
Results
Basal Nucleotide Concentrations in Airway Surface
Liquid in Vivo (Fig. 1)
The concentration of ATP in nasal ASL, after
correcting for dilution using urea measure-
ments, was 470  131 nM in normal subjects,
and 911  199 nM in CF subjects. These values
were not significantly different (p  0.18). Sim-
ilarly, no difference in UTP concentrations was
detected in nasal ASL from normal and CF
subjects (37.0  7.2 nM and 33.3  11.8 nM,
respectively; p  0.81; Fig. 1). To test nucleotide
stability in samples collected and stored by
these methods, we performed pilot experi-
ments that demonstrated the ATP concentration
measured in a lavage aliquot was not different,
whether assayed immediately after collection,
after a brief centrifugation to pellet any cells
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Fig. 1. Basal ATP and UTP concentrations in
airway surface liquid from normal and cystic
fibrosis (CF) subjects in vivo. (A) ATP concentrations
were measured by the luciferin-luciferase assay
(n  11, normal and CF). (B) UTP concentrations
were determined with an enzymatic assay and
high performance liquid chromatography (HPLC;
n  5, normal and CF). Nucleotide levels were
corrected for dilution using parallel urea 
measurements. The mean nucleotide 
concentrations  standard error of the mean
(SEM) are depicted.
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(600  g, 2 min), or after a freeze-thaw cycle
(variability 5% for all samples; data not
shown). To determine whether the presence of
extracellular nucleotides was the result of cel-
lular damage, we measured lactate dehydroge-
nase (LDH) activity in samples. LDH levels
were uniformly below detectable levels by this
method.
Basal ATP Release from Cultured Nasal Epithelial
Cells: Normal vs. CF (Fig. 2)
The maintenance of a basal NTP concentration
in vivo suggests that there may be a balance
between constitutive NTP release and metabo-
lism. To explore this possibility, we used cul-
tured, polarized airway epithelia as a model of
native airway epithelia. Although cultured air-
way cells have been shown in the past to re-
spond to “non-injurious” mechanical stimuli
by releasing ATP and UTP (25,27,30), ATP re-
lease from non-stimulated airway epithelial
cells has not been demonstrated previously. To
test for constitutive release, we used a protocol
that simultaneously measured the concentra-
tion of ATP in ASL and the rate of metabolism
of [32P]
ATP. A trace quantity of [32P]ATP
was introduced at time zero, and aliquots sub-
sequently were withdrawn at designated inter-
vals. The ATP concentration measured by the
luciferin-luciferase assay in aliquots from the
apical bath remained constant over time both
in normal (3.5  1.5 nM; n  3 patients; 4 cul-
tures/patient) and CF cultures (8.3 nM; n  2
patients; 4 cultures/patient). HPLC analysis of
the same samples, however, detected the rapid
hydrolysis of the terminal phosphate from
[32P]ATP, indicating ongoing ATP metabolism
(Fig. 2A). The observation of a constant ATP
concentration, despite ongoing ATP hydrolysis,
suggested that constitutive ATP release occurred
under these basal conditions at a rate that pre-
cisely offset the measured basal hydrolytic rate.
Importantly, the calculated rate of ATP release
Fig. 2. Constitutive ATP release from cultured
airway cells. (A) The basal ATP concentration and
[32P]ATP mass measured in the mucosal bath of
cultured cystic fibrosis (CF) tracheobronchial
epithelial cells. Values represent the percent of
initial values, obtained from three cultures from a
CF patient. A trace quantity of [32P]ATP was
added to the apical media overlying well-
differentiated tracheobronchial cells that had been
undisturbed for 3 hr. Sequential samples were
analyzed for ATP concentration using the luciferin-
luciferase assay, and [32P]ATP metabolism was
measured with high performance liquid
chromatography (HPLC). ATP concentration (open
circles) remained constant despite ongoing ATP
metabolism, as shown by the breakdown of
[32P]ATP (closed squares). The simultaneous
measurement of ATP concentration and initial
[32P]ATP metabolic rate allowed calculation of the
ATP release rate under these equilibrium conditions.
(B) The mean calculated rate of constitutive ATP
release ( standard error of the mean; SEM) from
normal (3 patients; 3–6 cultures/patient) and CF 
(2 patients; 3–6 cultures/patient) airway cells.
from normal (66.6  34.2 fmoles/min·cm2) and
CF (178.9 fmoles/min·cm2) cells were not sig-
nificantly different (p  0.21; Fig. 2B).
Basal ATP Release from Normal and CF Nasal
Mucosa in vivo (Fig. 3A)
To determine if normal and CF airways contin-
uously released ATP in vivo, we used a proto-
col employing continuous nasal perfusion with
warmed saline. Continuous perfusion resulted
in a nearly constant concentration of ATP in the
effluent within 2–3 min of initiating perfusion.
This steady-state concentration was main-
tained for more than 15 min in most experi-
ments, suggesting that ATP was released at a
rate equal to its removal by perfusion under
these conditions. Data from normal (N  5) 
and CF (N  5) subjects revealed no difference
in the mean steady-state rate of ATP release
(from minutes 3 to 15) during saline perfusion
(66.7  11.6 vs. 93.5  16.6 pmoles/min, 
respectively; p  0.26; Fig. 3A). LDH was 
below detectable levels in these samples.
Regulated Release of ATP from the Superficial
Epithelium in vivo (Fig. 3B)
We tested whether an agent that activates CFTR
chloride conductance by raising intracellular
cAMP also stimulated ATP release in vivo in
normal or CF subjects. Isoproterenol (10 M)
was delivered onto the nasal mucosa with a
hand-held nebulizer, followed by ASL sampling
as performed during basal [NTP] measurements.
The contralateral nostril was used for a vehicle
control. The ATP concentration measured in
these lavages was corrected for dilution using
urea concentration measurements. In these ex-
periments, we did not observe an increased ATP
concentration in lavages after isoproterenol treat-
ment compared with vehicle controls in either
normal or CF subjects (Fig. 3B).
Effect of Submucosal Gland Secretions on NTP
Concentrations in ASL (Fig. 4)
Because glands secrete the liquid lining nasal
surfaces, we hypothesized that submucosal
gland (SMG) secretions may act in series with
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Fig. 3. In vivo ATP release under basal
conditions and after isoproterenol treatment.
(A) Basal ATP release during continuous saline
perfusion (5 ml/min) was measured in vivo. Mean
data ( standard error of the mean; SEM) from
normal (open squares; n  5) and cystic fibrosis
(CF; solid circles; n  5) subjects is depicted. After
an initial wash-down in ATP concentration, a
stable level typically persisted for 15 min. The
inserted figure depicts the mean steady-state rate of
ATP release from normal and CF nasal mucosae.
(B) Comparison of isoproterenol vs. vehicle on ATP
release. Using a hand-held nebulizer, isoproterenol
(10 M) was applied to one nostril in normal
(n  5; solid circles) and CF (n  4; open squares)
subjects, and an equal volume of vehicle (.9% NaCl)
to the opposite nostril. Nasal lavages were per-
formed 2 min after applying the respective agents,
and ATP and urea concentrations were measured.
The ATP concentration after isoproterenol vs. vehicle
(corrected for dilution) from each patient is plotted
with respect to the line of unity (dashed line).
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the surface epithelia to regulate ASL ATP levels
in large airways. Two mechanisms predict that
SMG secretions would contain a large concen-
tration of nucleotides. First, as ATP is packaged
and released from granules in nerve (35,36) and
adrenal chromaffin cells (37), SMGs may also re-
lease ATP via an exocytotic mechanism. Second,
since CFTR is most abundantly expressed in
SMGs (38), CFTR-mediated nucleotide release
might be most readily detected in nasal lavages
from normal, as compared with CF, subjects
after stimulating SMG secretion. We tested
these hypotheses by stimulating SMG secretion
in vivo with a cholinergic agonist, followed by
Fig. 4. The effect of nasal submucosal gland
secretions on ATP concentration. (A) The ATP
concentration measured in nasal lavages (not
corrected for dilution) collected after stimulating
submucosal gland (SMG) secretion with
methacholine was reduced dramatically (closed
column), relative to basal lavages (open column).
(B) Exogenous ATP (1000 nM) added to nasal
lavages rapidly disappeared only in those obtained
after stimulating submucosal gland secretion
(squares), compared with baseline lavages 
(triangles). Boiling the secretion-rich lavage
abolished this enzyme activity (circles). (C) High
performance liquid chromatography (HPLC)
chromatogram demonstrating hydrolysis of the
terminal phosphate group from [33P]ATP (100 M)
in a nasal lavage enriched with SMG secretions. 
(D) The total concentration of adenine nucleotides
present in lavages before (open column) and after
(closed column) SMG stimulation was determined by
rephosphorylating all AMP and ADP in the sample to
ATP, followed by the luciferin-luciferase assay.
the luciferin-luciferase assay to measure the
ATP concentration.
In contrast to our hypotheses, the ATP con-
centration in lavages after stimulating gland
secretion was markedly lower than in basal
lavages from normal (Fig. 4A) and CF subjects.
This difference could not be attributed to simple
dilution of ASL nucleotides by gland secretions,
as the volume of gland secretions accounted for
only 10–15% of the final lavage volume. In-
stead, this marked decrease in ATP concentra-
tion reflected the presence of a secreted NTPase,
as evidenced by the observation that exogenous
ATP rapidly disappeared when added to nasal
lavages enriched with gland secretions (Fig. 4B).
Boiling lavages for 1 min prevented the metab-
olism of exogenously added ATP (Fig. 4B).
HPLC experiments using [33P]
ATP and
[33P]
UTP as substrates demonstrated that the
conversion of NTP to NDP occurred via cleavage
of the terminal phosphate group (Fig. 4C), thus
confirming the presence of a NTPase.
Selected ATPase and phosphatase in-
hibitors were tested to characterize the type of
NTPase activity present in SMG secretions.
Ouabain (1 mM), sodium orthovanadate (1 mM),
and tetramisole (5 mM) had no effect on the
observed ATPase activity. HgCl2, which was
reported to potently inhibit apyrase (CD39,
ATP dihydrophosphorylase), had no inhibitory
effect at concentrations up to 100 M (39).
Sodium azide (20 mM), an inhibitor of both 
F-type (mitochondrial) and E-type ATPases,
produced a 37  2.5% inhibition of enzyme
activity. Chelation of magnesium and calcium
resulted in a 90  3.5% loss of enzyme activity.
This panel of results was similar to that
reported for E-type ATPases (40). 
The secretion of a soluble NTPase caused
decreased ATP levels in lavages after SMG stimu-
lation and complicated testing the hypothesis
that release of ATP could occur from SMGs. To
assess ATP secretion in the presence of a NTPase,
we quantitatively rephosphorylated all AMP
and ADP in these nasal lavages to ATP, using
myokinase and pyruvate kinase, and then mea-
sured the final concentration of ATP with the
luciferin-luciferase assay. These experiments
demonstrated that the total amount of adenine
nucleotides in lavages from normal subjects
before and after cholinergic stimulation was
not different (Fig. 4D). These findings, there-
fore, suggested that SMGs were not a source of
extracellular adenine nucleotides.
Nucleotide Triphosphate Metabolism by a Soluble
NTPase (Fig. 5)
Because of the surprising finding that SMGs
secreted a soluble NTPase, we investigated its
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Fig. 5. ATPase activity in nasal lavages. ATPase activity in baseline lavages (B), after methacholine treatment
(M), and after ipratropium bromide followed by methacholine (I	M) from normal (n  4) and cystic fibrosis
(CF; n  3) patients. For comparisons, * denotes p  0.05, and ** denotes p  0.005.
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activity on the nasal surface of normal and CF
subjects under both basal conditions and after
submucosal gland stimulation (Fig. 5). Prior
to SMG stimulation, lavages from normal
subjects contained a small, but detectable,
amount of ATPase activity; whereas, basal lav-
ages from CF subjects had significantly more
activity (0.07  0.03 vs. 0.97  0.34 nmoles/
min·ml, respectively; p  0.05). After stimu-
lating SMG secretion with methacholine, a
markedly increased ATPase activity was ob-
served both in normal (3.02  0.46 nmoles/
min·ml) and CF (7.07  1.50 nmoles/ min·ml)
subjects (Fig. 5). Pretreatment with the cholin-
ergic receptor antagonist ipratropium bromide
nearly abolished the observed increase in 
ATPase activity in response to methacholine
(Fig. 5), demonstrating that the methacholine
induced effect was indeed a cholinergic recep-
tor mediated event and not a non-specific/
toxic reaction to the drug.
Nucleotide Triphosphate Metabolism by Airway
Epithelial Cultures
To test for nucleotide metabolism on normal
and CF airway superficial epithelial surfaces,
we measured the initial rates of ATP and UTP
metabolism on well-differentiated, cultured
nasal epithelial cells. CF epithelia demon-
strated a moderately increased apparent Vmax
for ATP hydrolysis (4.41  0.32 vs. 3.62  0.
30 nmoles/min·cm2; n  5 patients; p  .005)
and UTP hydrolysis (5.81  0.49 vs. 4.28 
0.41 nmoles/min·cm2; n  4 patients; p 
0.005) relative to normal nasal epithelial cells. 
Discussion
An important issue in the field of extracellular
nucleotide biology is whether ABC trans-
porters regulate the release of ATP. This issue
bears directly on the pathophysiology of CF,
because of earlier reports, emanating primarily
from in vitro cell culture models, describing a
role for CFTR in epithelial cell ATP release.
However, subsequent reports addressing the
role of CFTR in epithelial ATP release are re-
markable for their lack of consensus. Based on
their disparate findings, groups have concluded
that CFTR itself functions as an ATP channel
(7,9,13,41), is a regulator of a separate but as-
sociated channel (10,11), or has no relationship
to ATP transport whatsoever (25–29). Although
there has been much speculation over the fac-
tors leading to these differences (41–43), con-
troversy in this field continues to exist. We,
therefore, turned to a human in vivo system in
an attempt to ascertain the physiologic impor-
tance of CFTR-mediated ATP release. 
Using a lavage technique designed to min-
imize mechanical perturbation of the nasal ep-
ithelium, we measured basal levels of ATP in
nasal ASL from normal and CF subjects in vivo.
No significant difference in ATP concentrations
was found between normal and CF subjects
under these conditions (Fig. 1). We extended
these studies to UTP, because of its potency at
airway P2Y2 receptors and reports that UTP was
released by airway epithelia (30). Once again,
no difference in UTP concentrations between CF
and normal subjects was detected in vivo.
Although a normal and CF basal nucleotide
levels were similar within a given experimen-
tal system, a large discrepancy appeared to exist
between the resting levels of ATP in the media
bathing cultured epithelia (Fig. 2) and our urea-
corrected in vivo measurements (Fig. 1). To
more directly compare data from these different
experimental systems, we normalized the mass
of recovered ATP to the epithelial surface area
that was sampled. In the case of the in vivo
experimental system, the volume of ASL re-
covered was calculated by applying simple
dilution principles to the concentration of
urea measured in these samples. The epithelial
surface area associated with this ASL volume
then was determined by assuming that the
nasal ASL height approximated 50 M [based
on published figures for total nasal ASL vol-
ume (32) and surface area (44)]. Using this ap-
proach, the mean basal levels of ATP in ASL
were 2.36  1012 and 4.27  1012 moles/cm2
in normal and CF subjects, respectively. These
data are in remarkably close agreement with
the mean resting ATP levels measured in vitro,
where 1.6  1012 and 3.8  1012 moles/cm2
were measured in normal and CF cultures, res-
pectively. The consistency of these results suggest
that our in vitro cultures are indeed a good
model for the study of airway nucleotide re-
lease, and lessen the likelihood that our in vivo
results are spurious. Although this high degree
of correlation is reassuring, one must keep in
mind that several assumptions are incorpo-
rated into these calculations, including the
height of the nasal ASL layer in vivo. Perhaps
more importantly, we do not know whether
the concentration or number of moles bathing a
cultured epithelium might change as the vol-
ume of overlying media is reduced from the
“thick-film” conditions imposed by these
experiments (∼4000 M), to more physiologic
“thin-film” conditions (ASL 10–50 M in
height).
Although these data suggest that reduced
basal nucleotide concentrations do not contri-
bute to CF airways disease pathogenesis, they
do not definitively rule out the hypothesis that
CFTR is involved in ATP transport, because re-
duced nucleotide release by CF epithelia could
have been offset by reduced metabolism by
ecto-nucleotidases. We, therefore, directly mea-
sured rates of ATP release and extracellular me-
tabolism by normal and CF airway epithelial
cultures. Using a novel assay to measure basal
rates of ATP release under truly non-stimulated
conditions, we found no difference in the rates
of ATP release by normal and CF cultures
(Fig. 2). Similarly, rates of nucleotide metabo-
lism by CF airway cultures were not reduced,
but in fact modestly, though significantly, ele-
vated, compared with normal cultures. Together,
these data support the notion that the important
pathways for nucleotide release from cells are
intact in the CF epithelium. In addition, this
assay is the first to demonstrate that ATP release
occurs continuously during non-stimulated
conditions and, thus, provides a mechanism for
the maintenance of ATP levels in ASL in the
presence of active ecto-nucleotidases. 
The two prior reports of basal ATP release
from normal and CF epithelia differ in their
findings. These results (Fig. 2) are consistent
with those of Grygorczyk et al., who did not
detect differences in resting ATP concentra-
tions, nor mechanically stimulated ATP release,
between normal and CF epithelial cell lines
(27). Our results differ from Taylor et al. (14),
who detected significant basal ATP release
from normal but not CF cell lines. There are
differences in the bioluminescent assays used
to detect ATP release that may contribute to
these discrepant results. The assay we devel-
oped avoids mechanically stimulated ATP
release (e.g. washing cells, changing media, or
movement of the culture plate) and is the first
to incorporate measurements of endogenous
nucleotide metabolism, thus, allowing deter-
mination of ATP release rates without limita-
tion by concomitant ectonucleotidase activity.
Perhaps more importantly, our study is the first
to directly compare normal and CF primary
cultured cells, rather than immortalized cell
lines.
Although our in vitro studies allowed us to
examine nucleotide release and metabolism
under non-stimulated conditions, the lack of
suitable reagents precluded direct measure-
ment of metabolism in vivo. Measurements of
ATP release, however, were feasible. Slow,
continuous perfusion of the nasal epithelium
with warmed saline was associated with a
rapid reduction of the ATP concentration in the
superfusate over the first 2–3 min, followed by
steady-state levels. The initial peak in ATP lev-
els may reflect washout of ATP preexistent on
the mucosal surface, and/or mechanically stim-
ulated ATP release resulting from catheter
placement and the initiation of perfusion. Be-
cause perfusion served to reduce the effects of
extracellular metabolism, the lower steady-
state levels reflected the rate of ATP release.
Like the measurements made in vitro, the ATP
release rates measured in normal and CF sub-
jects were not different (Fig. 3A). Cell lysis as
the source of the measured ATP seems unlikely,
because cell damage, in response to slow saline
perfusion, would need to occur at a constant
rate to produce the observed constant ATP con-
centration during 15 min of perfusion. 
Two approaches were employed to test
whether regulated release of ATP occurred in
vivo and if it was dependent on CFTR function.
First, we explored the regulation of ASL ATP
concentration by -adrenergic receptor agonists.
No increase in ATP levels was detected in vivo
in normal subjects (or CF) in response to iso-
proterenol, suggesting that cAMP was not able
to stimulate ATP release from the superficial ep-
ithelium via CFTR activation (Fig 3B). Second,
because CFTR is most abundantly expressed in
glandular epithelia (38), we tested the hypoth-
esis that normal glands, when stimulated,
would vigorously secrete ATP; whereas, CF
glands might be expected to exhibit defective
ATP secretion. These experiments detected no
significant release of ATP from submucosal
glands in either group and, instead, revealed
the secretion of a soluble NTPase from both nor-
mal and CF glands. Together, these experiments
support the notion that CFTR-mediated ATP re-
lease is not biologically relevant in airways.
In addition to addressing the hypothesis
that CFTR regulates ATP release, our data have
implications for the physiology of the P2Y2 re-
ceptor system in airways in vivo. Our data pro-
vide the first in vivo measurements of nucleotide
concentrations in ASL. The measured basal ATP
concentration of ∼0.5–1.0 M approximates the
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concentration at which chloride secretion can
first be detected in vivo using the nasal potential
difference technique (45). Relatively small in-
creases in ATP release, therefore, might lead to a
rapid increase in chloride secretion and, per-
haps, accelerate mucociliary clearance rates. This
basal ATP concentration would also be unlikely
to cause receptor desensitization, as has been
shown to occur experimentally at higher nu-
cleotide concentrations in heterologous cells
(46). The much lower concentration of UTP in
ASL (Fig. 1) suggests that ATP is the more phys-
iologically important P2Y2 agonist in vivo.
The finding that glands secrete a NTPase
also adds to our understanding of nucleotide
receptor regulation in airways. Although the
paradigm for extracellular nucleotide metabo-
lism generally has been limited to cell-attached
ecto-nucleotidases, growing precedent exists
for secreted nucleotidases. Relevant to our
findings are reports of secreted ATPase and
ATP-diphosphohydrolases (ATPDase) activi-
ties from other glandular tissues such as ovi-
duct (47,48) and prostate (49). In these tissues,
an ATPDase may be secreted into the luminal
compartment via microvesicular shedding from
the plasma membrane (50). Our finding of
cholinergic receptor-mediated ATPase secre-
tion from SMGs suggests that the rate of glan-
dular secretion in vivo provides a means of reg-
ulating nucleotide concentrations on airway
surfaces. Whether gland hypersecretion in dis-
eases such as CF and chronic bronchitis re-
duces lower airway ATP concentration, with a
potential consequence being reduced mucocil-
iary clearance rates, will be important to study.
In summary, our data show that: (1) the
basal concentrations of ATP and UTP in nasal
ASL in vivo are not reduced in CF; (2) rates of
ATP release from CF epithelia are not reduced
either in vitro or in vivo; and, (3) cAMP does not
regulate ATP release. These findings suggest
that CFTR-mediated nucleotide release does not
play an important role in determining the extra-
cellular NTP concentrations in vivo or a patho-
physiologic role in the development of CF lung
disease. Our data do indicate that ATP is present
in the ASL of normal and CF subjects at concen-
trations well-suited for the dynamic regulation
of mucociliary clearance via P2Y2 receptors.
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